Contact Us

If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

You can contact us by phone, fax, or email, or by filling out the form below.

Are you a patient with a question?
Consumer Affairs
Phone: 1-888-508-6978
Fax: 610-290-9729
Email: cslb-consumeraffairs@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Are you a healthcare professional with a product-related question?
Medical Information
Phone: 1-800-504-5434
Fax: 610-878-4550
Email: medinfona@cslbehring.com
(Standard business hours are 9:00 am - 5:00 pm ET)
Would you like to report an undesirable effect with use of a CSL Behring product?
If you experience any undesirable side effect(s) with a CSL Behring product, talk to your doctor, pharmacist, or nurse. If you would like to report the side effect(s) to CSL Behring, please contact us at:
CSL Behring US Pharmacovigilance
Phone: 1-866-915-6958
Email: Adverse.Events.Global@cslbehring.com
(Available 24 hrs/day)
You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Do you have a media-related question or comment?
Corporate Media Inquiries
Chris Florentz
Phone: 610-878-4316
Fax: 610-290-9316
Product-Related Media Inquiries
Anthony Farina
Phone: 610-878-4665
Fax: 610-290-9665
(Standard business hours are 8:30 am - 5:00 pm ET)
Do you have a question or comment about CSL Plasma or the plasma donation process?
CSL Plasma

Visit the CSL Plasma website to get more information on donating plasma or to send your questions and comments.

For all other questions, please contact...
CSL Behring Headquarters, North America
Phone: 610-878-4000
Fax: 610-878-4009
Address:

PO Box 61501
1020 First Avenue
King of Prussia, PA 19406-0901 USA

(Standard business hours are 8:30 am - 5:00 pm ET)

Comments/Inquiries Form

Type the verification text in the box below:

Verification Word
By submitting this form, you are consenting to receive an email response with relevant information from CSL Behring. You may also receive relevant information from CSL Behring in the future. You will have the ability to opt out from receiving CSL Behring emails or mailings at any time. View our Privacy Policy here.
MTL14-07-0006(1) 11/2015

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.

Zemaira may not be suitable for everyone; for example, people with known hypersensitivity to components used to make Zemaira, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.

Early signs of hypersensitivity reactions to Zemaira include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.

Because Zemaira is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

CSL Behring

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® and CareZ® are registered trademarks of CSL Behring LLC.

© 2017 CSL Behring. The product information presented on this site is intended for US residents only.
ZMR14-04-0006 7/2014